Strontium ranelate

Stroncium-ranelate is used in medicine as an  anti-osteoporotic agent , which has a dual mechanism of action on bone – it increases bone formation and at the same time reduces bone osteoresorption. It is also effective in the elderly and in clinically risky situations (e.g. in the case of bone fragility syndrome). The strontium ranelate molecule contains two Sr 2+ ions bound to an organic carrier – ranelic acid.

Indication
Long-term treatment reducing the risk of vertebral and non-vertebral fractures or fractures of the proximal femur in complicated osteoporosis. The treatment is primarily intended for the treatment of osteoporosis in women after menopause and for the treatment of osteoporosis in men with an increased risk of fractures.

Contraindications
Venous thromboembolism (also in the anamnesis), cardiovascular diseases (ischemic heart disease, strokes, arterial hypertension, diseases of peripheral arteries).

Interactions
The bioavailability of strontium ranelate is reduced by the simultaneous administration of milk, milk products and preparations containing calcium, as well as some antacids. On the other hand, strontium ranelate reduces the absorption of tetracycline and quinolone antibiotics. Simultaneous administration of bisfosphonates or raloxifeneis considered inappropriate.

Adverse effects
The most common adverse effects leading to discontinuation of treatment were nausea and diarrhea, headaches or skin reactions. Very common side effects include musculoskeletal pain. Common ones include cardiovascular disorders (thromboembolism, acute myocardial infarction), hepatitis, bronchial hyperreactivity,vertigo and others. As of January 2014, the use of strontium renelate is not recommended.

Method of administration and dosage
In the Czech Republic, strontium ranelate is State Drug Control Office: strontium ranelateavailable in sachets for the preparation of an oral suspension. In the treatment of osteoporosis, 2 g of strontium ranelate is administered daily in a single dose (usually at bedtime 2 hours after dinner). The treatment is long-term.

Related Articles

 * Osteoporosis
 * Osteoporosis therapy

External references

 * Restrictions in administration of strontium ranelate from SÚKL